Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy - PubMed (original) (raw)
Affiliations
- PMID: 11489793
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy
G J Veal et al. Clin Cancer Res. 2001 Aug.
Abstract
The formation of platinum (Pt)-DNA adducts is thought to be crucial to the antitumor activity of cisplatin, and relationships between adduct formation in peripheral blood leukocytes (PBLs) and response to cisplatin therapy have been reported. The current study directly tests, for the first time, whether pharmacokinetic or other factors predominantly determine the drug-target interaction of cisplatin in a pediatric patient population. Cisplatin pharmacokinetics and Pt-DNA adduct formation in PBLs were determined in 10 children in parallel with measurement of adduct levels after incubation of pretreatment blood samples with cisplatin in vitro. Total and unbound plasma Pt concentrations were determined by atomic absorption spectrophotometry and adduct measurements performed by competitive ELISA. Pt-DNA adduct levels determined after cisplatin treatment showed considerable interindividual variation (peak levels at 24 h ranged from 0.15 to 1.31 nmol/g DNA) and correlated strongly with adduct levels determined after incubation of pretreatment whole blood with cisplatin (r = 0.92; P = 0.0002). No significant correlation was observed between in vivo adduct formation and either unbound or total cisplatin plasma concentrations (r = 0.14 and 0.18, respectively). A correlation was also observed between the degree of myelosuppression, as determined by WBC nadirs measured over a 14-day period after cisplatin treatment, and the extent of adduct formation, with greater WBC toxicity observed in patients with higher levels of Pt-DNA adducts (P = 0.010). These preliminary results provide evidence that interpatient variation in formation of Pt-DNA adducts in PBLs of children is determined by host-specific factors other than cisplatin pharmacokinetics. These results imply that analysis of adducts in PBLs after incubation of pretreatment blood samples with cisplatin may be used to predict in vivo adduct levels, leukopenia, and, potentially, response to cisplatin therapy.
Similar articles
- Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R. Bonetti A, et al. Clin Cancer Res. 1996 Nov;2(11):1829-35. Clin Cancer Res. 1996. PMID: 9816137 Clinical Trial. - Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F. Fichtinger-Schepman AM, et al. Cancer Res. 1990 Dec 15;50(24):7887-94. Cancer Res. 1990. PMID: 2253228 - Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR. Peng B, et al. Br J Cancer. 1997;76(11):1466-73. doi: 10.1038/bjc.1997.579. Br J Cancer. 1997. PMID: 9400943 Free PMC article. - Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG, Campbell SL, Bassett E, Wu Y. Chaney SG, et al. Crit Rev Oncol Hematol. 2005 Jan;53(1):3-11. doi: 10.1016/j.critrevonc.2004.08.008. Crit Rev Oncol Hematol. 2005. PMID: 15607931 Review. - Comparative clinical pharmacology of cisplatin and carboplatin.
Murry DJ. Murry DJ. Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):140S-145S. Pharmacotherapy. 1997. PMID: 9322881 Review.
Cited by
- Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.
Vaughn CM, Selby CP, Yang Y, Hsu DS, Sancar A. Vaughn CM, et al. J Biol Chem. 2020 May 29;295(22):7584-7594. doi: 10.1074/jbc.RA120.013347. Epub 2020 Apr 16. J Biol Chem. 2020. PMID: 32299912 Free PMC article. - Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2020 Jan 21;1(1):CD010885. doi: 10.1002/14651858.CD010885.pub5. Cochrane Database Syst Rev. 2020. PMID: 31961948 Free PMC article. - Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2019 May 7;5(5):CD009219. doi: 10.1002/14651858.CD009219.pub5. Cochrane Database Syst Rev. 2019. PMID: 31063591 Free PMC article. - Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2018 Jul 5;7(7):CD010885. doi: 10.1002/14651858.CD010885.pub4. Cochrane Database Syst Rev. 2018. PMID: 29975402 Free PMC article. Updated. Review. - Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ. White-Koning M, et al. Eur J Cancer. 2018 Mar;91:56-67. doi: 10.1016/j.ejca.2017.11.029. Epub 2018 Jan 12. Eur J Cancer. 2018. PMID: 29335155 Free PMC article.